PWG
VRTX icon

Portside Wealth Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Portside Wealth Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61M Buy
5,258
+434
+9% +$192K 0.3% 74
2026
Q1 		$2.15M Buy
4,824
+510
+12% +$238K 0.29% 82
2025
Q4 		$1.96M Buy
4,314
+571
+15% +$246K 0.26% 82
2025
Q3 		$1.47M Buy
3,743
+545
+17% +$228K 0.2% 114
2025
Q2 		$1.42M Buy
3,198
+253
+9% +$117K 0.21% 107
2025
Q1 		$1.43M Buy
2,945
+679
+30% +$316K 0.23% 102
2024
Q4 		$913K Buy
2,266
+261
+13% +$121K 0.15% 148
2024
Q3 		$932K Buy
2,005
+193
+11% +$92.7K 0.16% 146
2024
Q2 		$849K Buy
1,812
+30
+2% +$13K 0.16% 142
2024
Q1 		$745K Buy
1,782
+126
+8% +$53.3K 0.14% 161
2023
Q4 		$674K Buy
1,656
+144
+10% +$53.2K 0.13% 176
2023
Q3 		$522K Buy
1,512
+226
+18% +$79K 0.1% 189
2023
Q2 		$453K Buy
+1,286
New +$433K 0.08% 208

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

Portside Wealth Group's VRTX Position: Q2 2026 in Review

Portside Wealth Group increased its Vertex Pharmaceuticals (VRTX) stake by 9% in Q2 2026, buying an estimated $192K and bringing the position to 5,258 shares worth $2.61M. The position accounts for 0.3% of the portfolio, ranked #74.

Portside Wealth Group first reported a position in VRTX in Q2 2023 and has held it in 13 quarters since. 252 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Portside Wealth Group held 5,258 shares of Vertex Pharmaceuticals worth $2.61M as of Q2 2026.
  • Portside Wealth Group bought 434 Vertex Pharmaceuticals shares in Q2 2026, an estimated $192K.
  • Vertex Pharmaceuticals made up 0.3% of Portside Wealth Group's portfolio in Q2 2026, its #74 holding.
  • Portside Wealth Group first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 252 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Portside Wealth Group's 13F filing for Q2 2026, filed 14 Jul 2026.